Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Provides Update on Beacon Mill Restart and Exploration Updates (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today!

ACCESS Newswire August 5, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ:ALLR) for potential violations of federal securities laws

ACCESS Newswire August 4, 2024

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALLR

Newsfile August 4, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today!

ACCESS Newswire August 4, 2024

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm!

ACCESS Newswire August 2, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws

PR Newswire August 2, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

PR Newswire August 1, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm!

ACCESS Newswire August 1, 2024

Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating Allarity Therapeutics, Inc. for Potential Violations of Federal Securities Laws

ACCESS Newswire August 1, 2024

ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc.

ACCESS Newswire July 31, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws

PR Newswire July 31, 2024

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm!

ACCESS Newswire July 31, 2024

Levi & Korsinsky Announces an Investigation on Behalf of Allarity Therapeutics, Inc. (ALLR) Shareholders Who May Have Been Affected by Fraud

ACCESS Newswire July 31, 2024

ALLR Investors Can Join The Allarity Therapeutics Inc Securities Fraud Investigation With The Schall Law Firm

ACCESS Newswire July 31, 2024

Levi & Korsinsky Reminds Shareholders of an Investigation into Allarity Therapeutics, Inc. (ALLR) Regarding Potential Securities Fraud Allegations

ACCESS Newswire July 30, 2024

Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Allarity Therapeutics, Inc. for Potential Violations of Federal Securities Laws

ACCESS Newswire July 30, 2024

Shareholder Rights Advocates at Levi & Korsinsky Investigate Allarity Therapeutics, Inc. (ALLR) Regarding Possible Securities Fraud Violations

ACCESS Newswire July 30, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

ACCESS Newswire July 30, 2024

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

Business Wire July 30, 2024

ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc.

ACCESS Newswire July 30, 2024